INDUSTRY × Hematologic Diseases × Clear all
NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Ossium Health, Inc.

Phase 1/2 Recruiting
12 enrolled
NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Pfizer

Phase 2 Completed
39 enrolled 15 charts
NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled
NCT04996875 2025-05-30

APEX

Cogent Biosciences, Inc.

Phase 2 Recruiting
140 enrolled
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Celularity Incorporated

Phase 1 Unknown
29 enrolled
NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Takeda

Phase 1/2 Completed
35 enrolled 36 charts
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Merck Sharp & Dohme LLC

Phase 3 Completed
637 enrolled 15 charts